Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women
Introduction: Oral antihyperglycaemic prescription trends keep on changing and thus the drug prescription trend study may prove to be powerful exploratory tool for health care providers. Aim: To investigate trends in prescriptions of oral antihyperglycaemic drugs (OHDs) among postmenopausal wome...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2016-01-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/7063/16044_CE[Ra1]_F(AK)_PF1(EKAK)_PFA(AK)_PF2(PAG).pdf |
id |
doaj-948b2db272a44ae5bc6bc850e0768691 |
---|---|
record_format |
Article |
spelling |
doaj-948b2db272a44ae5bc6bc850e07686912020-11-25T03:03:50ZengJCDR Research and Publications Private LimitedJournal of Clinical and Diagnostic Research2249-782X0973-709X2016-01-01101OC11OC1510.7860/JCDR/2016/16044.7063Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal WomenSudhaa Sharma0Vishal R. Tandon1Roshi2Annil Mahajan3Post Graduate Student, Department of Obstetrics and Gyanecology, Government Medical College Jammu- J&K, India.Post Graduate Student, Department of Pharmacology, Government Medical College Jammu- J&K, India.Post Graduate Student, Department of Pharmacology, Government Medical College Jammu- J&K, India.Professor and Head, Department of General Medicine, Government Medical College Jammu- J&K, India.Introduction: Oral antihyperglycaemic prescription trends keep on changing and thus the drug prescription trend study may prove to be powerful exploratory tool for health care providers. Aim: To investigate trends in prescriptions of oral antihyperglycaemic drugs (OHDs) among postmenopausal women suffering from T2DM in India and evaluate the rationality and adherence to ADA treatment guidelines. Materials and Methods: An observational, crosssectional descriptive prescription audit (n=500) was carried. Postmenopausal women were interviewed in their local language using pre-tested pre validated questionnaire after verbal informed consent at a teaching tertiary care hospital of north India. Oral antihyperglycaemic drugs (OHDs) drugs were categorized as per the pharmacological classification. Adherence to available clinical practice guidelines/recommendations issued under American Diabetes Association (ADA) 2015 Guidelines as well as rationality of these prescriptions were assessed using WHO Guide to Good Prescribing. Results: Mean age of the study population was 58.14±12.86. Mean duration since menopause was 5.3 years and of T2DM was 9.5 years. A 93.4% of the prescriptions had only OHDs whereas 6.6% of the prescriptions had various insulin preprations + OHDs (p<0.0001). Biguanides followed by sulfonylureas, thiazolidinediones, DPP-inhibitors and alpha-glucosidases inhibitor were prescribed in 85.6%, 59.8%, 26.6%, 26% and 12.2% respectively as monotherapy or in combination. Among biguanides, metformin was the most frequently prescribed OHDs. In spite of black box warning on pioglitazone, it was prescribed in 26.6% as FDC. However, clear increase use of vidagliptine was noticed upto 26%. Among combinations most frequent was metformin plus glimipride followed by voglibose plus metformin, whereas, among FDC, metformin plus glimipride followed by metformin plus vidagliptine were most frequently prescribed. Conclusion: Metformin was the most common OHDs to be prescribed followed by glimepiride. Although pioglitazone still continues to be prescribed after safety alert but apparently it appears that the share of pioglitazone has been shifted to vidagliptin or combinations like metformin plus glimipride. Polypharmacy, high use of FDC, & prescription by brand names were some of the irrationalities. Relatively low adherence to ADA treatment guidelines was observed.https://jcdr.net/articles/PDF/7063/16044_CE[Ra1]_F(AK)_PF1(EKAK)_PFA(AK)_PF2(PAG).pdforal antihyperglycaemicprescription trendstype 2 diabetes mellitus |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sudhaa Sharma Vishal R. Tandon Roshi Annil Mahajan |
spellingShingle |
Sudhaa Sharma Vishal R. Tandon Roshi Annil Mahajan Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women Journal of Clinical and Diagnostic Research oral antihyperglycaemic prescription trends type 2 diabetes mellitus |
author_facet |
Sudhaa Sharma Vishal R. Tandon Roshi Annil Mahajan |
author_sort |
Sudhaa Sharma |
title |
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
title_short |
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
title_full |
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
title_fullStr |
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
title_full_unstemmed |
Prescribing Pattern of Oral Antihyperglycaemic Drugs, Rationality and Adherence to American Diabetes Association (ADA) Treatment Guidelines among Type 2 Diabetes Mellitus (T2DM) Postmenopausal Women |
title_sort |
prescribing pattern of oral antihyperglycaemic drugs, rationality and adherence to american diabetes association (ada) treatment guidelines among type 2 diabetes mellitus (t2dm) postmenopausal women |
publisher |
JCDR Research and Publications Private Limited |
series |
Journal of Clinical and Diagnostic Research |
issn |
2249-782X 0973-709X |
publishDate |
2016-01-01 |
description |
Introduction: Oral antihyperglycaemic prescription trends keep
on changing and thus the drug prescription trend study may prove
to be powerful exploratory tool for health care providers.
Aim: To investigate trends in prescriptions of oral
antihyperglycaemic drugs (OHDs) among postmenopausal women
suffering from T2DM in India and evaluate the rationality and
adherence to ADA treatment guidelines.
Materials and Methods: An observational, crosssectional descriptive prescription audit (n=500) was carried.
Postmenopausal women were interviewed in their local language
using pre-tested pre validated questionnaire after verbal informed
consent at a teaching tertiary care hospital of north India. Oral
antihyperglycaemic drugs (OHDs) drugs were categorized as per
the pharmacological classification. Adherence to available clinical
practice guidelines/recommendations issued under American
Diabetes Association (ADA) 2015 Guidelines as well as rationality
of these prescriptions were assessed using WHO Guide to Good
Prescribing.
Results: Mean age of the study population was 58.14±12.86.
Mean duration since menopause was 5.3 years and of T2DM
was 9.5 years. A 93.4% of the prescriptions had only OHDs
whereas 6.6% of the prescriptions had various insulin preprations
+ OHDs (p<0.0001). Biguanides followed by sulfonylureas,
thiazolidinediones, DPP-inhibitors and alpha-glucosidases
inhibitor were prescribed in 85.6%, 59.8%, 26.6%, 26% and
12.2% respectively as monotherapy or in combination. Among
biguanides, metformin was the most frequently prescribed OHDs.
In spite of black box warning on pioglitazone, it was prescribed
in 26.6% as FDC. However, clear increase use of vidagliptine
was noticed upto 26%. Among combinations most frequent was
metformin plus glimipride followed by voglibose plus metformin,
whereas, among FDC, metformin plus glimipride followed by
metformin plus vidagliptine were most frequently prescribed.
Conclusion: Metformin was the most common OHDs to be
prescribed followed by glimepiride. Although pioglitazone still
continues to be prescribed after safety alert but apparently
it appears that the share of pioglitazone has been shifted to
vidagliptin or combinations like metformin plus glimipride.
Polypharmacy, high use of FDC, & prescription by brand names
were some of the irrationalities. Relatively low adherence to ADA
treatment guidelines was observed. |
topic |
oral antihyperglycaemic prescription trends type 2 diabetes mellitus |
url |
https://jcdr.net/articles/PDF/7063/16044_CE[Ra1]_F(AK)_PF1(EKAK)_PFA(AK)_PF2(PAG).pdf |
work_keys_str_mv |
AT sudhaasharma prescribingpatternoforalantihyperglycaemicdrugsrationalityandadherencetoamericandiabetesassociationadatreatmentguidelinesamongtype2diabetesmellitust2dmpostmenopausalwomen AT vishalrtandon prescribingpatternoforalantihyperglycaemicdrugsrationalityandadherencetoamericandiabetesassociationadatreatmentguidelinesamongtype2diabetesmellitust2dmpostmenopausalwomen AT roshi prescribingpatternoforalantihyperglycaemicdrugsrationalityandadherencetoamericandiabetesassociationadatreatmentguidelinesamongtype2diabetesmellitust2dmpostmenopausalwomen AT annilmahajan prescribingpatternoforalantihyperglycaemicdrugsrationalityandadherencetoamericandiabetesassociationadatreatmentguidelinesamongtype2diabetesmellitust2dmpostmenopausalwomen |
_version_ |
1724684372185972736 |